Business Context and Reporting Period
This Form 6-K filing by Galmed Pharmaceuticals Ltd. covers the month of July 2026. The report addresses a regulatory matter concerning the Company's listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing compliance rather than financial performance.
Material Changes
The primary material event is the Company's receipt of a letter from Nasdaq on July 30, 2026, granting an additional 180-day compliance period. The Company previously failed to maintain the minimum $1.00 bid price per share for 30 consecutive trading days, a deficiency first notified on January 29, 2026. The initial compliance period ended on July 28, 2026, without the Company regaining compliance.
Outlook, Risks, and Contingencies
- Compliance Deadline: The Company now has until January 25, 2027, to regain compliance with Nasdaq Listing Rule 5550(a)(2).
- Compliance Criteria: To close the matter, the bid price of the Company's ordinary shares must close at or above $1.00 per share for a minimum of 10 consecutive trading days before the new deadline.
- Risk of Delisting: Failure to meet the $1.00 bid price requirement by January 25, 2027, may result in delisting proceedings.
Investor Verification Checklist
- Verify the current trading price of Galmed Pharmaceuticals Ltd. shares to assess proximity to the $1.00 threshold.
- Monitor the stock's closing price over the next 10 consecutive trading days to determine if compliance is achieved.
- Review the Company's capital structure and potential actions (e.g., reverse stock split) that may be taken to address the bid price deficiency.
- Confirm the status of the Company's other Nasdaq listing requirements beyond the minimum bid price.